Meeting
2019 ASCO Annual Meeting
Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).
Authors
Erika Paige Hamilton
Tennessee Oncology, PLLC and Sarah Cannon Research Institute, Nashville, TN
Erika Paige Hamilton , Elizabeth Claire Dees , Judy Sing-Zan Wang , Amy Kim , Manav Korpal , Vicki Rimkunas , Nathalie Rioux , Joanne Schindler , Dejan Juric
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03250676
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1059)
DOI
10.1200/JCO.2019.37.15_suppl.1059
Abstract #
1059
Poster Bd #
140
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges
Poster
2023 ASCO Annual Meeting
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.
First Author: Elisa Agostinetto
Poster
2022 ASCO Annual Meeting
ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
First Author: Erika P. Hamilton
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye